PHAXIAM Therapeutics S.A. Company Overview
About PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics (EPA:PHXM), (NASDAQ:PHXM) pioneers cutting-edge solutions in pharmaceuticals, focused on transforming lives through innovative therapies. Specializing in precision medicine, PHAXIAM harnesses the power of advanced technologies and deep scientific expertise to develop targeted treatments for challenging diseases. With a commitment to patient-centric care, the company strives for breakthroughs in areas such as oncology, immunology, and rare genetic disorders. PHAXIAM's robust pipeline is propelled by a culture of collaboration, drawing on interdisciplinary insights to drive impactful advancements in healthcare. Positioned at the forefront of therapeutic innovation, PHAXIAM Therapeutics is dedicated to shaping a healthier future for global communities.
Snapshot
Operations
Produtos e/ou serviços de PHAXIAM Therapeutics S.A.
- Precision Oncology Therapies: PHAXIAM Therapeutics specializes in developing precision oncology therapies tailored to individual patient profiles, aiming to revolutionize cancer treatment and improve patient outcomes.
- Immunomodulatory Drugs: PHAXIAM's immunomodulatory drugs target the immune system, offering novel approaches to treating autoimmune diseases, inflammatory disorders, and other conditions where immune responses play a central role.
- Rare Disease Treatments: PHAXIAM is dedicated to addressing the unmet needs of patients with rare genetic disorders by developing innovative therapies that target the underlying molecular mechanisms of these conditions.
- Personalized Medicine Platforms: PHAXIAM leverages advanced personalized medicine platforms to identify biomarkers, predict treatment responses, and tailor therapies to individual patients, optimizing efficacy and minimizing side effects.
- Therapeutic Antibodies: The company's portfolio includes therapeutic antibodies designed to selectively target disease-associated antigens, offering precise and potent treatment options across a range of therapeutic areas.
- Clinical Research Services: PHAXIAM provides comprehensive clinical research services, including study design, patient recruitment, data analysis, and regulatory support, to advance the development of novel therapeutics from early-stage research through to market approval.
equipe executiva do PHAXIAM Therapeutics S.A.
- Mr. Eric Soyer Ph.D.Deputy CEO, Deputy GM, CFO & COO
- Dr. Jérôme Bailly Pharm.D.Deputy CEO, Deputy GM, Chief Quality Officer & Qualified Person
- Mr. Thibaut du FayetChief Executive Officer
- Ms. Céline BredaChief Technology Officer
- Ms. Cindy FevreChief Scientific Officer
- Naomi EichenbaumDirector Investor Relations
- Ms. Anne-Cécile FumeyVice President of Human Resources
- Ms. Karine Charton Ph.D.Chief Business Officer
- Dr. Pascal Birman M.D.Chief Medical Officer
- Ms. Frederique VievilleChief Regulatory Officer